X4 Pharmaceuticals (XFOR)
Commercializing XOLREMDI while advancing mavorixafor for chronic neutropenia.
$4.01
Pre-market−0.04 (−0.87%)
At close$4.05(−0.61%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions81 holders · as of Mar 31, 2026 | 91.22% | 90.44M shares | |
| Insiders15 holders · as of Aug 13, 2026 | 0.95% | 938.2K shares | |
| Otherremainder | 7.83% | 7.77M shares |
99.15M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
81 holders · 90.44M shares · 18 new positions · 39 increased · 22 reduced · 12 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Morgan Stanley | 9.47M | 9.55% | +1.26M | May 15, 2026 |
| Empery Asset Management, LP | 8.94M | 9.02% | −7.0K | May 8, 2026 |
| FMR LLC | 8.10M | 8.17% | −395.7K | May 15, 2026 |
| Bain Capital Life Sciences Investors, LLC | 7.97M | 8.04% | 0 | May 15, 2026 |
| Perceptive Advisors LLC | 6.74M | 6.80% | +423.2K | May 29, 2026 |
| Saturn V Capital Management LLC | 6.46M | 6.51% | +656.1K | May 15, 2026 |
| Deep Track Capital, LP | 6.34M | 6.39% | +1.33M | May 15, 2026 |
| Kalehua Capital Management LLC | 3.72M | 3.75% | 0 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Morgan Stanley | 10.20% | 8.88M | 13G | Mar 6, 2026 ↗ |
| Empery Asset Management, LP | 9.99% | 9.04M | 13G | Jan 15, 2026 ↗ |
| Coastlands Capital LP | 9.99% | 2.49M | 13G | Oct 3, 2025 ↗ |
| Deep Track Capital, LP | 9.99% | 2.37M | 13G | Aug 19, 2025 ↗ |
| Coastlands Capital LLCincl. Coastlands Capital LP, Coastlands Capital Partners LP +2 more | 9.99% | 2.48M | 13D | Aug 18, 2025 ↗ |
| BCLS II Investco, LPincl. BCIP Life Sciences Associates, LP, Bain Capital Life Sciences Fund II, L.P. +2 more | 9.99% | 2.44M | 13D | Aug 13, 2025 ↗ |
| FMR LLC | 9.70% | 8.50M | 13G | Feb 5, 2026 ↗ |
| Saturn V Capital Management LP | 7.36% | 6.43M | 13G | Feb 17, 2026 ↗ |
| Perceptive Advisors LLC | 7.30% | 6.89M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 6.70% | Nov 8, 2024 ↗ | ||
| Growth Equity Opportunities 18 VGE, LLCincl. Anthony A. Florence, Jr., Mohamad H. Makhzoumi +9 more | 6.20% | 5.06M | 13D | Oct 29, 2025 ↗ |
| Trails Edge Capital Partners, LP | 5.80% | 5.23M | 13G | Feb 17, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 12, 2026 | John Volponeofficer: President | Sale | 24,576 | $4.44 | 265,305 |
| Aug 12, 2026 | Adam R. Craigdirector, officer: Executive Chairman | Sale | 47,436 | $4.44 | 328,651 |
| Jun 30, 2026 | David Kirskeofficer: Chief Financial Officer | Sale | 8,543 | $4.26 | 167,750 |
| May 12, 2026 | David Kirskeofficer: Chief Financial Officer | Sale | 16,961 | $4.29 | 176,293 |
| Oct 23, 2025 | Adam R. Craigdirector, officer: Executive Chairman | Purchase | 86,206 | $2.90 | 376,087 |
CongressHouse and Senate disclosures
Not reported.